QYUNS-B (02509) intends to acquire approximately 34.0001% of the shares of Sifushi.

Notification of QYUNS-B (02509): On June 26, 2026, Sifujuli (a wholly-owned subsidiary of our company) entered into a share transfer agreement with Taizhou Huacheng. Sifujuli conditionally agreed to acquire, while Taizhou Huacheng conditionally agreed to sell the target shares (approximately 34.0001% of the shares of Sifushi) for a price of 86.02 million RMB. The share transfer will be completed on the day when the relevant authorities complete the registration of the share change (Sifujuli must complete the payment and sign the share transfer agreement within 30 business days). As of the date of this announcement, our company indirectly owns approximately 65.9999% of the shares of Sifushi through Sifujuli. After the acquisition is completed, our company will indirectly own 100% of the shares of Sifushi through Sifujuli. Sifushi will become a wholly-owned subsidiary of our company, and its financial performance will continue to be consolidated into the comprehensive financial statements of our group. Sifushi is our subsidiary dedicated to CMC, mainly responsible for the development of cell lines, process development, formulation development, analytical method development, quality control, quality assurance, pilot production, and commercial production for our group. The purpose of the acquisition is to facilitate the smooth submission and approval of new drug applications for the group's core pipeline products, Rucexita monoclonal antibody (QX002N, anti-IL-17A monoclonal antibody) and Ottochibai monoclonal antibody (QX005N, anti-IL-4R monoclonal antibody). It also aims to integrate the resources of our group, enhance internal synergy, optimize management structure, and further improve the governance efficiency and operational efficiency of Sifushi. The board of directors believes that the acquisition is in line with the overall business development strategy of our group, and believes that it is beneficial to the overall management of our group's business. The target shares are state-owned assets, and the transfer of the target shares has been approved by the state-owned asset supervision department and conducted through public listing. Additionally, after the completion of the acquisition, our company's shareholding in Sifushi will increase from approximately 65.9999% to 100%. The board believes that the acquisition is strategically aligned with the goals of our group, namely accelerating the approval of core products, enhancing synergy, and improving operational and management efficiency.